51 results about "Clinical marker" patented technology

Multiplexed lateral flow assays, related methods, and devices are disclosed which are capable of simultaneously detecting multiple analytes. The assays are preferably immunoassays and can be multiplexed spatially, spectrally, and both spatially and spectrally. Multiplexed assays are disclosed employing quantum dots for applications including the detection of human proteins and the monitoring of microorganisms relevant to water contamination. The multiplexed assays can employ one or more species of Surface Enhanced Raman Scattering nanoparticles, with one or more species having a unique Raman shift spectrum. The invention is widely adaptable to a variety of analytes such as biowarfare agents, human clinical markers, and other substances.

The present invention relates to methods, monitors and systems measuring lysophosphatidylcholine, its derivatives and / or procalcitonin as well as at least one clinical marker (e.g. temperature or respiration rate) and / or at least one biomarker for the early detection of sepsis in a subject.

An MRI image processing and analysis system may identify instances of structure in MRI flow data, e.g., coherency, derive contours and / or clinical markers based on the identified structures. The system may be remotely located from one or more MRI acquisition systems, and perform: perform error detection and / or correction on MRI data sets (e.g., phase error correction, phase aliasing, signal unwrapping, and / or on other artifacts); segmentation; visualization of flow (e.g., velocity, arterial versus venous flow, shunts) superimposed on anatomical structure, quantification; verification; and / or generation of patient specific 4-D flow protocols. An asynchronous command and imaging pipeline allows remote image processing and analysis in a timely and secure manner even with complicated or large 4-D flow MRI data sets.

The present invention inter alia provides a method, and use thereof, of diagnosing and / or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and / or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of atherosclerosis or CVD.

The present invention relates to a group of epilepsy biomarkers comprising (i) SNP rs2740574; (ii) SNP rs1799735; (iii) SNP rs1695; (iv) SNP rs6280; and the locus of the human glutathione S-transferase theta-1 (GSTT1) gene. The invention particularly relates to this group of biomarkers as marker for protection against drug-resistant epilepsy. The group of biomarkers may additionally comprise at least one clinical marker selected from the group comprising (i) a focal seizure with secondary generalization; (ii) age at confirmed diagnosis of epilepsy; (iii) atrophy of hippocampus or medial temporal sclerosis; and (iv) the presence of a brain tumor. The present invention further relates to a method for detecting protection against drug-resistant epilepsy in a subject, a method for monitoring epilepsy therapy, a method of identifying an individual as eligible for an aggressive epilepsy therapy, a composition for detecting protection against drug-resistant epilepsy in a subject, a corresponding kit and a microarray for the analysis of protection against drug-resistant epilepsy.

A sensor is provided that is appropriate for optical detection of dissolved carbon dioxide. Such a sensor may be used for transcutaneous detection of carbon dioxide in the tissue. Alternatively, such sensors may be inserted into the tissue. Detection of dissolved carbon dioxide in the tissue may serve as a useful clinical marker for physicians.

A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity. Another method is based upon gene expression predictive biomarkers assessed via RNA expression in peripheral blood cell samples collected prior to treatment with the compound, which is also used for treating patients afflicted with pancreatic cancer.

In a method and computer for evaluating medical image data of an examination subject, a clinical marker of the examination subject is acquired that characterizes a status of the examination subject in relation to a physiological parameter, and a normal value range for the physiological parameter is ascertained that is matched to the status of the examination subject as a function of the clinical marker. Medical image data of the examination subject are acquired, and a value of the physiological parameter of the examination subject is determined using the medical image data. This value is compared with the normal value range matched to the status of the examination subject, and the result of the comparison is provided as an output.

As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over-expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer.

A method of detecting whether or not a body chamber has an abnormal structure or function including: (a) providing a stack of images as input to a system comprising one or more hardware processors configured to obtain a stack of medical images comprising at least a representation of the body chamber inside the patient; to obtain a region of interest using a convolutional network trained to locate the body chamber, wherein the region of interest corresponds to the body chamber from each of the medical images; and to infer a shape of the body chamber using a stacked auto-encoder (AE) network trained to delineate the body chamber, wherein the AE network segments the body chamber; (b) operating the system to detect the body chamber in the images using deep convolutional networks trained to locate the body chamber, to infer a shape of the body chamber using a stacked auto-encoder trained to delineate the body chamber, and to incorporate the inferred shape into a deformable model for segmentation; and (c) detecting whether or not the body chamber has an abnormal structure, wherein an abnormal structure is indicated by a body chamber clinical indicia that is different from a corresponding known standard clinical indicia for the body chamber.

The invention discloses a method for constructing an evaluation model for the biological age of a Chinese population based on clinical markers. The method comprises the following steps: (1) selectingclinical routine markers representing different pathophysiological systems or functions; (2) constructing a biological age evaluation model by utilizing the selected markers based on a KDM algorithm;(3) evaluating the obtained biological age evaluation model, and if the effect of the model is poor, returning to the steps (1) and (2) and carrying out the next round of model construction operation,or if the effect meets requirements, outputting the constructed biological age evaluation model. The method can be applied to early identification and prevention of aging of people in China and intervention effect evaluation of senile diseases, and has practicability and huge application potential.

The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and / or treating CVD complications. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of CVD complications.

The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of statin-induced muscle toxicity.

The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of statin-induced muscle toxicity.